MEIP News and Press, MEI Pharma Inc. From 11/30/21

– Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – MEI to Host Webcast Today at 8:00am Eastern Time – ...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study ...

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Mr. Sujay Kango to its board of directors effective November 22, 2021. "We are very happy to welcome Sujay, an industry leader with ...

Last week was mixed for the penny stocks and higher-priced ones alike. While there were plenty of trends to follow, some continued gaining steam heading into the middle of November. Sure, you’ve got things like metaverse stocks, short squeeze penny stocks , and your typical low f...

MEI Pharma (NASDAQ:MEIP): FQ1 GAAP EPS of -$0.13 misses by $0.01. Revenue of $13.39M (+249.6% Y/Y) beats by $2.84M. Press Release For further details see: MEI Pharma EPS misses by $0.01, beats on revenue

-TIDAL Study Data on Track to be Reported by End of Calendar Year 2021- -MEI Begins Second Fiscal Quarter with ~$145.5 Million in Cash- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported ...

MEI Pharma (NASDAQ:MEIP) and Kyowa Kirin announce that the U.S. FDA granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma. Orphan-drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which gener...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to ...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that three abstracts highlighting data and information from three oncology drug candidates in its pipeline will be presented at the upcoming 63 rd Annu...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 136,000 shares of the company’s common stock to three new employees. The stock options wer...